Cytochrome P450 Symposium

The technical advances in genomics in the last decades have made it possible to tailor medical treatments based on the genetic background of the individual patient. This has a huge potential to improve the treatment for the individual patient by fasten recovery, decrease side effects, and overall to be of benefit not only for the patient, but also for the society.

The cytochrome P450 (CYP450) superfamily is central for drug metabolism and genotype variation of the CYP450 family is potentially a key determinant explaining the substantial person-to-person and between-population differences in pharmacokinetics, and by extension, highly variable clinical effects of medicines. Thus, a genomic testing of CYP450 genotype can add biomarker guidance in the decision making process of selecting the right medication to the right patient. Genotyping CYP450 tests have been developed but are primarily used e.g. when initial antidepressant treatments don’t show clinical benefits. The aim of this workshop is to get a current overview of the role of the CYP450 system and its central role in drug metabolism and why CYP450 tests are not applied more in the clinical setting as well as discussing future perspectives and trends of CYP450 in relation to personalised medicine.